BioMarin Pharmaceutical (BMRN) is back in focus after its Phase 3 CANOPY-HCH-3 trial of Voxzogo in children with hypochondroplasia met primary and key secondary endpoints, with no new safety findings reported.

The Voxzogo update comes as BioMarin's share price, at US$52.88, has seen short term momentum pick up with a 7 day share price return of 6.16%. However, the 1 year total shareholder return is down 9.00% and the 3 year total shareholder return is down 39.37%. This suggests that recent optimism follows a tougher multi year run.

If this kind of rare disease pipeline interests you, it can also be useful to look across the sector and see which other healthcare AI and data driven stocks are on the move through the 34 healthcare AI stocks

With BioMarin sharing positive trial news while the stock sits well below analyst targets and longer term returns remain weak, the key question is clear: is this a fresh opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 41.2% Undervalued

With BioMarin trading at $52.88 against a widely followed fair value narrative of $89.96, the current gap centers on future earnings power and margins.

Recent acquisition of Inozyme and ongoing business development initiatives broaden BioMarin's enzyme therapy portfolio and introduce new high-value therapies targeting severe unmet needs, enhancing diversification and durability of revenue streams over the long term. Company's operational leverage and disciplined cost management as new products move from R&D to commercial stage, combined with efforts to improve patient adherence and maximize market penetration, are likely to support margin expansion and drive earnings growth.

Want to see what sits behind that confidence in future earnings and margins? The narrative leans on ambitious revenue growth, fatter profit margins, and a lower future earnings multiple than today. The specific mix of those three inputs is what drives that $89.96 fair value target.

Result: Fair Value of $89.96 (UNDERVALUED)

However, there are clear pressure points, including Voxzogo competition and pricing, as well as higher R&D and integration costs around deals like Inozyme and the planned Amicus acquisition.

Another Angle on Valuation

The first narrative leans on future earnings power and a fair value of $89.96. Yet on current numbers BioMarin trades on a P/E of 38x versus 18.9x for peers, and a fair ratio of 23x. That kind of premium can shrink quickly, so is the discount story really so clear cut?

Next Steps

With sentiment clearly split between risks and rewards, you may want to look at the numbers yourself and decide quickly where you stand based on the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you are weighing up BioMarin today, it can be smart to line it up against other stocks that fit clear, focused criteria using the Simply Wall Street Screener.

• Target potential mispricings and see which companies currently look out of favor by fundamentals through the 46 high quality undervalued stocks.
• Strengthen your watchlist with companies that pair robust finances with staying power using the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by checking a screener containing 22 high quality undiscovered gems that the market may not be paying close attention to yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.